Therapeutic Targets
With our lead drug candidate, CRX-100, we have used an intellectual property portfolio, developed by the company’s founders and exclusively licensed from Stanford University, to create a first-in-class immunotherapy that pairs the power of an oncolytic virus with the tumor-locating ability of cytokine-induced killer (CIK) cells.
16744
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16744,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
 

Therapeutic Targets

Acute Myeloid Leukemia

 

Acute myeloid leukemia (AML) is a blood disorder characterized by uncontrolled proliferation of a type of immature white blood cells called “myeloid cells”, which causes failure of the bone marrow to function properly. AML is the most common type of leukemia in adults.

 

 

COVID-Associated Acute Lung Injury

 

Acute lung injury is a rapidly progressive form of respiratory failure that occurs in some people, especially the elderly or those with pre-existing illness, who are infected with COVID-19. It is the major cause of morbidity and mortality that is associated with COVID-19 infection.

 

 

“Long-Haul COVID-19”

 

Approximately 10% of COVID-19 infected patients develop “long hauler” complications: persistent debilitating and disabling myalgic encephalitis/chronic fatigue syndrome-like symptoms of fatigue, shortness of breath, muscle aches, and “brain fog”. The prevalence of long-haulers in U.S. is estimated at 2 million and will continue to rise in advance of vaccine availability: a major public health issue. These symptoms can persist indefinitely despite virus clearance, in many cases without any resolution. There is no known treatment for “long-haulers” other than supportive care; vaccines and other antiviral measures are unlikely to have a treatment effect for “long haulers”. To quickly address this growing crisis and enable widespread usage, a therapy ideally should be oral, safe, in Phase II or later development, and subject to rapid scale-up of manufacturing and distribution if efficacy is confirmed. Dicopp® meets these criteria.

 

 

Other inflammatory lung disorders

 

Disulfiram and copper, the constituents of Dicopp® in a proprietary formulation, inhibit the activity of inflammasomes, key drivers of life-threatening inflammatory conditions, COPD exacerbations, and other common pulmonary inflammatory disorders such as severe refractory asthma and community-acquired pneumonia.

 

 

Recurrent/refractory multiple myeloma

 

Although great strides have been made in the treatment of myeloma, relapse is common, and the disease tends to become more refractory with each successive line of treatment. New treatments, especially those with lesser side effects, are greatly needed.

microscope and Doctor holding tablet